Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus target price of $1.50 for the company and are anticipating that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned Cesca Therapeutics an industry rank of 112 out of 255 based on the ratings given to related companies.

Several equities analysts have commented on the stock. ValuEngine upgraded shares of Cesca Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. HC Wainwright assumed coverage on shares of Cesca Therapeutics in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $1.50 price target for the company.

NASDAQ:KOOL opened at $0.25 on Friday. The firm has a market capitalization of $6.94 million, a price-to-earnings ratio of -0.26 and a beta of -0.95. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.61 and a quick ratio of 0.79. Cesca Therapeutics has a 52 week low of $0.22 and a 52 week high of $6.44.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.